Russia announced that its experimental cancer vaccine, Enteromix, had completed preclinical trials with promising results, raising hopes for a potential breakthrough in cancer treatment. Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), shared the news at the Eastern Economic Forum in Vladivostok, per Newsweek. The vaccine is now awaiting official approval for use.
Skvortsova reported that Enteromix reduced tumours by 60-80%, depending on the cancer type, and improved survival rates in preclinical tests spanning three years. Initially targeting colorectal cancer, the vaccine is also being developed for glioblastoma and melanoma, including ocular melanoma. While some media claimed 100% efficacy, Newsweek could not confirm this, urging caution until further data is released.
💉🇷🇺 #Enteromix | #Russia's #mRNA #cancer #vaccine ready to use, shows #tumour shrinking results: Report 🧬📊 https://t.co/RcQGmcwKUj pic.twitter.com/m0VWySUmtn
— Economic Times (@EconomicTimes) September 7, 2025The FMBA is preparing Enteromix for clinical trials, pending regulatory approval. Skvortsova stated the vaccine is “ready for use” but requires final authorisation. Researchers aim to expand its application to other cancers, building on the trial’s success in reducing tumour sizes, per Newsweek.
Enteromix’s promising results offer hope for cancer patients worldwide, especially for hard-to-treat cancers like colorectal and glioblastoma. If approved, it could mark a major step in cancer treatment. However, unverified claims about efficacy highlight the need for rigorous testing and transparency.
